Lv31
290 积分 2024-09-18 加入
Current treatment landscape for patients with non–small cell lung cancer with common EGFR mutations
1小时前
待确认
The changing treatment landscape of EGFR-mutant non-small-cell lung cancer
3小时前
已完结
Glecirasib plus sitneprotafib in patients with KRASG12C-mutated non-small-cell lung cancer in China: an open-label, multicentre, single-arm, phase 1/2a trial
8天前
已完结
EP08.02-140 MET Biomarker-based Preliminary Efficacy Analysis in SAVANNAH: savolitinib+osimertinib in EGFRm NSCLC Post-Osimertinib
21天前
已完结
Savolitinib in patients in China with locally advanced or metastatic treatment-naive non-small-cell lung cancer harbouring MET exon 14 skipping mutations: results from a single-arm, multicohort, multicentre, open-label, phase 3b confirmatory study
22天前
已完结
High levels of AXL expression in untreated EGFR‐mutated non‐small cell lung cancer negatively impacts the use of osimertinib
1个月前
已完结
A retrospective study of the efficacy of combined EGFR‑TKI plus VEGF inhibitor/cytotoxic therapy vs. EGFR‑TKI monotherapy for PD‑L1‑positive EGFR‑mutant non‑small cell lung cancer: North Japan Lung Cancer Study Group 2202
1个月前
已完结
Efficacy of Salvage Treatments in Relapsed or Refractory Diffuse Large B-Cell Lymphoma Including Chimeric Antigen Receptor T-Cell Therapy: A Systematic Review and Meta-Analysis
1个月前
已完结
Treatment of relapsed/refractory MCL
1个月前
已完结
IBCL-413: Real-World Treatment Patterns and Clinical Outcomes in Patients With Marginal Zone Lymphoma
1个月前
已完结
皖公网安备34019202002308
